Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vivos Therapeutics, Inc. (VVOS)
|
Add to portfolio |
|
|
|
| Price: |
$2.26
| | Metrics |
| OS: |
29.9
|
M
| |
|
|
| Market cap: |
$67.6
|
M
| |
|
|
|
Net cash:
|
$2.74
|
M
| |
$0.09
|
per share
|
|
EV:
|
$64.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 16.9 | 13.1 | 11.4 | 3.8 |
| Revenue growth | 29.2% | 14.7% | 200.4% | |
| Cost of goods sold | 0.1 | 0.1 | 2.7 | 1.1 |
| Gross profit | 16.8 | 13.0 | 8.7 | 2.7 |
| Gross margin | 99.4% | 99.2% | 76.0% | 71.5% |
| Sales and marketing | 5.6 | 2.3 | 2.3 | 1.2 |
| General and administrative | 25.8 | 16.1 | 16.2 | 9.3 |
| EBITA | -19.2 | -8.3 | -10.2 | -8.3 |
| EBITA margin | -113.5% | -63.6% | -89.1% | -219.8% |
| Amortization of intangibles | 0.3 | 0.4 | 0.4 | |
| EBIT | -19.5 | -8.7 | -10.6 | -8.3 |
| EBIT margin | -115.3% | -66.7% | -92.8% | -219.8% |
| Pre-tax income | -20.3 | -12.1 | -10.8 | -8.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -20.3 | -18.0 | -11.8 | -9.4 |
| Net margin | -120.2% | -137.7% | -103.2% | -248.9% |
| |
| Diluted EPS | ($0.96) | ($1.40) | ($0.95) | ($0.82) |
| Shares outstanding (diluted) | 21.2 | 12.9 | 12.3 | 11.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|